These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25407518)

  • 1. Role of decorin in multiple myeloma (MM) bone marrow microenvironment.
    Nemani N; Santo L; Eda H; Cirstea D; Mishima Y; Patel C; O'Donnell E; Yee A; Raje N
    J Bone Miner Res; 2015 Mar; 30(3):465-70. PubMed ID: 25407518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.
    Huang SY; Lin HH; Yao M; Tang JL; Wu SJ; Hou HA; Chou WC; Chou SC; Hsu SC; Ko BS; Lu HY; Tsay W; Tien HF
    PLoS One; 2015; 10(9):e0137552. PubMed ID: 26379028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Runx2 Deficiency in Osteoblasts Promotes Myeloma Progression by Altering the Bone Microenvironment at New Bone Sites.
    Xu X; Zhang C; Trotter TN; Gowda PS; Lu Y; Ponnazhagan S; Javed A; Li J; Yang Y
    Cancer Res; 2020 Mar; 80(5):1036-1048. PubMed ID: 31911552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of decorin in the antimyeloma effects of osteoblasts.
    Li X; Pennisi A; Yaccoby S
    Blood; 2008 Jul; 112(1):159-68. PubMed ID: 18436739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New approaches to targeting the bone marrow microenvironment in multiple myeloma.
    Gooding S; Edwards CM
    Curr Opin Pharmacol; 2016 Jun; 28():43-9. PubMed ID: 27018230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
    Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple myeloma as a model for the role of bone marrow niches in the control of angiogenesis.
    Ribatti D; Nico B; Vacca A
    Int Rev Cell Mol Biol; 2015; 314():259-82. PubMed ID: 25619720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
    Kupisiewicz K
    Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple myeloma hinders erythropoiesis and causes anaemia owing to high levels of CCL3 in the bone marrow microenvironment.
    Liu L; Yu Z; Cheng H; Mao X; Sui W; Deng S; Wei X; Lv J; Du C; Xu J; Huang W; Xia S; An G; Zhou W; Ma X; Cheng T; Qiu L; Hao M
    Sci Rep; 2020 Nov; 10(1):20508. PubMed ID: 33239656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone marrow plasma level of decorin may be associated with improved treatment outcomes in a subset of multiple myeloma patients.
    Huang SY; Lin HH; Yao M; Tang JL; Wu SJ; Chou WC; Hsu SC; Ko BS; Tien HF
    J Formos Med Assoc; 2022 Mar; 121(3):643-651. PubMed ID: 34246509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Bone Marrow Microenvironment.
    Moschetta M; Kawano Y; Podar K
    Cancer Treat Res; 2016; 169():63-102. PubMed ID: 27696259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment.
    Klein B; Seckinger A; Moehler T; Hose D
    Recent Results Cancer Res; 2011; 183():39-86. PubMed ID: 21509680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cytokines and myeloma bone disease].
    Abe M
    Clin Calcium; 2014 Jun; 24(6):871-8. PubMed ID: 24870838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
    Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
    Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The microenvironment and molecular biology of the multiple myeloma tumor.
    Lemaire M; Deleu S; De Bruyne E; Van Valckenborgh E; Menu E; Vanderkerken K
    Adv Cancer Res; 2011; 110():19-42. PubMed ID: 21704227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma.
    Heath DJ; Chantry AD; Buckle CH; Coulton L; Shaughnessy JD; Evans HR; Snowden JA; Stover DR; Vanderkerken K; Croucher PI
    J Bone Miner Res; 2009 Mar; 24(3):425-36. PubMed ID: 19016584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-18 inhibits lodging and subsequent growth of human multiple myeloma cells in the bone marrow.
    Yamashita K; Iwasaki T; Tsujimura T; Sugihara A; Yamada N; Ueda H; Okamura H; Futani H; Maruo S; Terada N
    Oncol Rep; 2002; 9(6):1237-44. PubMed ID: 12375027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
    Tai YT; Li XF; Breitkreutz I; Song W; Neri P; Catley L; Podar K; Hideshima T; Chauhan D; Raje N; Schlossman R; Richardson P; Munshi NC; Anderson KC
    Cancer Res; 2006 Jul; 66(13):6675-82. PubMed ID: 16818641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.
    Bolzoni M; Storti P; Bonomini S; Todoerti K; Guasco D; Toscani D; Agnelli L; Neri A; Rizzoli V; Giuliani N
    Exp Hematol; 2013 Apr; 41(4):387-97.e1. PubMed ID: 23178378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple myeloma bone marrow niche.
    Basak GW; Srivastava AS; Malhotra R; Carrier E
    Curr Pharm Biotechnol; 2009 Apr; 10(3):345-6. PubMed ID: 19355944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.